Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer bought 11,085 shares of Adverum Biotechnologies stock in a transaction dated Friday, December 5th. The stock was acquired at an average cost of $4.24 per share, for a total transaction of $47,000.40. Following the purchase, the chief executive officer directly owned 83,899 shares in the company, valued at approximately $355,731.76. The trade was a 15.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Laurent Fischer also recently made the following trade(s):

• On Monday, December 8th, Laurent Fischer acquired 117,614 shares of Adverum Biotechnologies stock. The shares were bought at an average cost of $4.31 per share, with a total value of $506,916.34.

Adverum Biotechnologies Price Performance

Shares of Adverum Biotechnologies stock traded up $0.10 during trading on Monday, hitting $4.36. 987,543 shares of the company were exchanged, compared to its average volume of 447,123. The firm's fifty day moving average price is $4.41 and its 200 day moving average price is $3.35. Adverum Biotechnologies, Inc. has a 1-year low of $1.78 and a 1-year high of $6.12. The firm has a market capitalization of $96.26 million, a P/E ratio of -0.51 and a beta of 0.87.

Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.80) by ($0.23). As a group, equities research analysts anticipate that Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current year.

Institutional Investors Weigh In On Adverum Biotechnologies

Several institutional investors have recently bought and sold shares of ADVM. Y Intercept Hong Kong Ltd acquired a new position in Adverum Biotechnologies during the 2nd quarter worth approximately $45,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Adverum Biotechnologies in the third quarter worth $58,000. XTX Topco Ltd acquired a new position in Adverum Biotechnologies during the second quarter worth $64,000. Qube Research & Technologies Ltd acquired a new position in Adverum Biotechnologies during the second quarter worth $66,000. Finally, Marshall Wace LLP bought a new position in Adverum Biotechnologies in the second quarter valued at $107,000. Institutional investors own 48.17% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ADVM. HC Wainwright reaffirmed a "neutral" rating and set a $5.00 price objective (down previously from $30.00) on shares of Adverum Biotechnologies in a research note on Monday, November 17th. Chardan Capital lowered Adverum Biotechnologies from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 27th. Mizuho set a $5.50 price objective on Adverum Biotechnologies in a research report on Wednesday, October 29th. Royal Bank Of Canada set a $4.00 target price on Adverum Biotechnologies in a research note on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adverum Biotechnologies in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $10.50.

View Our Latest Research Report on Adverum Biotechnologies

About Adverum Biotechnologies

(Get Free Report)

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.

Recommended Stories

• Five stocks we like better than Adverum Biotechnologies
• 3 Stocks to Consider Buying in October
• What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health
• How to Invest in Tech Stocks and Top Tech Stocks to Consider
• 3 Stocks Most Likely to Split in 2026
• What is a Bond Market Holiday? How to Invest and Trade
• ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Adverum Biotechnologies Right Now?

Before you consider Adverum Biotechnologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.

While Adverum Biotechnologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here